Status:

RECRUITING

Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction

Lead Sponsor:

Odense University Hospital

Collaborating Sponsors:

University of Copenhagen

Université de Nantes

Conditions:

Neurogenic Dysfunction of the Urinary Bladder

Multiple Sclerosis

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

A multi-center double-blinded placebo-controlled randomized clinical trial. The patients will be randomized into two groups. To investigate the efficacy of SNM to improve the key bladder diary varia...

Detailed Description

Patients with MS often suffer from pelvic-organ dysfunctions, i.e. lower urinary tract (LUT), bowel and sexual dysfunction, aside their cerebral affection. Sacral neuromodulation (SNM) is a reversible...

Eligibility Criteria

Inclusion

  • Refractory neurogenic lower urinary tract dysfunction (nLUTD) defined by visual analogue scale on treatment satisfaction ranging from 0 to 100 (100 means maximal satisfaction with the current treatment). All patients indicating satisfaction less than 50 are considered non-responders/having refractory overactive bladder (OAB) to current treatment
  • No effect of medical treatment defined by antimuscarinics, beta3-agonist and alpha-blocker.
  • Patients having refractory nLUTD who intend to try SNM for relief of their symptoms
  • Expanded Disability Status Scale (EDSS) \< 5 and no progression of neurological disease within 6 months
  • Written informed consent
  • Able to understand the information given about the project

Exclusion

  • EDSS \> 5, neurological disease with severe progression within the last 6 months and/or unable to manage the electronic devices
  • Age \< 18 years
  • Any other urological pathology but nLUTD
  • Bladder Pain Syndrome/Interstitial cystitis
  • Any other intestinal or gynecological pathology but neurological conditional symptoms
  • Current pelvic malignancy or clinically significant pelvic mass
  • Previous pelvis radiotherapy
  • Bladder injections with botulinum neurotoxin type A within 6 months before inclusion in trial
  • Unable to manage the electronic devices
  • Inability to give an informed consent

Key Trial Info

Start Date :

September 26 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2027

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT05380856

Start Date

September 26 2023

End Date

March 1 2027

Last Update

March 20 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Odense University Hospital

Odense, Fyn, Denmark, 5000